Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.5
4.5
Journals
Biomimetics
Special Issues
Biomimetic Drug Delivery Systems
share announcement

Biomimetic Drug Delivery Systems

A special issue of Biomimetics (ISSN 2313-7673). This special issue belongs to the section "Development of Biomimetic Methodology".

Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 11078

Special Issue Editor

Dr. Junge Chen

E-Mail Website
Guest Editor
School of Engineering Medicine, Beihang University, Beijing, China
Interests: exosome drug delivery; precision diagnosis and therapy of tumor; liquid metal micro-nano robot
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Biomimetic drug delivery systems are a new type of drug delivery system that emerged rapidly in recent years. Extracts, isolates and various natural particles such as mammalian cells, endogenous proteins and pathogens from humans, animals and microorganisms simulate their basic structural functions in the form of in vitro recombination. Biomimetic drug delivery systems have drawn extensive attention because of their excellent biocompatibility, lower immunogenicity, and the ease of mimicking the bio-structure and function of biological systems, making them promising drug delivery systems.

This Special Issue on Biomimetic Drug Delivery Systems calls for contributions from scientists and researchers working in all areas of biomimetic drug delivery systems, and welcomes original research, theoretical, experimental and review papers about biomimetic hydrogels, biomimetic micelles, biomimetic liposomes, biomimetic dendrimers, biomimetic polymeric carriers, biomimetic nanostructures, exosome drug delivery systems, membrane-functional drug delivery systems, among others.

Dr. Junge Chen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomimetics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomimetics
  • drug delivery system
  • exosomes
  • hydrogels
  • micelles
  • liposomes
  • good targeting
  • low immunogenicity

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

24 pages, 4573 KiB  
Article
Biosynthesis Strategy of Gold Nanoparticles and Biofabrication of a Novel Amoxicillin Gold Nanodrug to Overcome the Resistance of Multidrug-Resistant Bacterial Pathogens MRSA and E. coli
by Eman M. S. Halawani, Seham S. S. Alzahrani and Sanaa M. F. Gad El-Rab
Biomimetics 2023, 8(6), 452; https://doi.org/10.3390/biomimetics8060452 - 25 Sep 2023
Cited by 1 | Viewed by 1077
Abstract
The prevalence of multidrug-resistant (MDR) bacteria has recently increased dramatically, seriously endangering human health. Herein, amoxicillin (Amoxi)-conjugated gold nanoparticles (AuNPs) were created as a novel drug delivery system to overcome MDR bacteria. MDR bacteria were isolated from a variety of infection sources. Phenotype, [...] Read more.
The prevalence of multidrug-resistant (MDR) bacteria has recently increased dramatically, seriously endangering human health. Herein, amoxicillin (Amoxi)-conjugated gold nanoparticles (AuNPs) were created as a novel drug delivery system to overcome MDR bacteria. MDR bacteria were isolated from a variety of infection sources. Phenotype, biotype, and 16S rRNA gene analyses were used for isolate identification. Additionally, Juniperus excelsa was used for the production of AuNPs. The conjugation of AuNPs with Amoxi using sodium tri-polyphosphate (TPP) as a linker to produce Amoxi-TPP-AuNPs was studied. The AuNP and Amoxi-TPP-AuNP diameters ranged from 15.99 to 24.71 nm, with spherical and hexagonal shapes. A total of 83% of amoxicillin was released from Amoxi-TPP-AuNPs after 12 h, and after 3 days, 90% of the medication was released. The Amoxi-TPP-AuNPs exhibited superior antibacterial effectiveness against MRSA and MDR E. coli strains. Amoxi-TPP-AuNPs had MICs of 3.6–8 µg mL−1 against the tested bacteria. This is 37.5–83 fold higher compared to values reported in the literature. Amoxi-TPP-AuNPs exhibit a remarkable ability against MRSA and E. coli strains. These results demonstrate the applicability of Amoxi-TPP-AuNPs as a drug delivery system to improve therapeutic action. Full article
(This article belongs to the Special Issue Biomimetic Drug Delivery Systems)
►▼ Show Figures

Figure 1

10 pages, 2316 KiB  
Article
Development of 3D-Bioprinted Colitis-Mimicking Model to Assess Epithelial Barrier Function Using Albumin Nano-Encapsulated Anti-Inflammatory Drugs
by Abdulmajeed G. Almutary, Abdullah M. Alnuqaydan, Saleh A. Almatroodi, Hamid A. Bakshi, Dinesh Kumar Chellappan and Murtaza M. Tambuwala
Biomimetics 2023, 8(1), 41; https://doi.org/10.3390/biomimetics8010041 - 18 Jan 2023
Viewed by 2512
Abstract
Physiological barrier function is very difficult to replicate in vitro. This situation leads to poor prediction of candidate drugs in the drug development process due to the lack of preclinical modelling for intestinal function. By using 3D bioprinting, we generated a colitis-like condition [...] Read more.
Physiological barrier function is very difficult to replicate in vitro. This situation leads to poor prediction of candidate drugs in the drug development process due to the lack of preclinical modelling for intestinal function. By using 3D bioprinting, we generated a colitis-like condition model that can evaluate the barrier function of albumin nanoencapsulated anti-inflammatory drugs. Histological characterization demonstrated the manifestation of the disease in 3D-bioprinted Caco-2 and HT-29 constructs. A comparison of proliferation rates in 2D monolayer and 3D-bioprinted models was also carried out. This model is compatible with currently available preclinical assays and can be implemented as an effective tool for efficacy and toxicity prediction in drug development. Full article
(This article belongs to the Special Issue Biomimetic Drug Delivery Systems)
►▼ Show Figures

Figure 1

17 pages, 4610 KiB  
Article
Facile Fabrication of Methyl Gallate Encapsulated Folate ZIF-L Nanoframeworks as a pH Responsive Drug Delivery System for Anti-Biofilm and Anticancer Therapy
by Saeed M. Marji, Mohammad F. Bayan and Abdolelah Jaradat
Biomimetics 2022, 7(4), 242; https://doi.org/10.3390/biomimetics7040242 - 16 Dec 2022
Cited by 10 | Viewed by 2099
Abstract
Zeolitic imidazole frameworks are emerging materials and have been considered an efficient platform for biomedical applications. The present study highlights the simple fabrication of methyl gallate encapsulated folate-ZIF-L nanoframeworks (MG@Folate ZIF-L) by a simple synthesis. The nanoframeworks were characterized by different sophisticated instruments. [...] Read more.
Zeolitic imidazole frameworks are emerging materials and have been considered an efficient platform for biomedical applications. The present study highlights the simple fabrication of methyl gallate encapsulated folate-ZIF-L nanoframeworks (MG@Folate ZIF-L) by a simple synthesis. The nanoframeworks were characterized by different sophisticated instruments. In addition, the drug-releasing mechanism was evidenced by in vitro releasing kinetics at various pH conditions. The anti-biofilm potential confirmed by the biofilm architectural deformations against human infectious pathogens MRSA and N7 clinical strains. Furthermore, anticancer efficacy assessed against A549 lung cancer cells. The result reveals that the MG@Folate ZIF-L exposed a superior cytotoxic effect due to the pH-responsive and receptor-based drug-releasing mechanism. Based on the unique physicochemical and biological characteristics of nanoframeworks, it has overcome the problems of undesired side effects and uncontrolled drug release of existing drug delivery systems. Finally, the in vitro toxicity effect of MG@Folate ZIF-L was tested against the Artemia salina (A. salina) model organism, and the results show enhanced biocompatibility. Overall, the study suggested that the novel MG@Folate ZIF-L nanoframeworks is a suitable material for biomedical applications. It will be very helpful to the future design for targeted drug delivery systems. Full article
(This article belongs to the Special Issue Biomimetic Drug Delivery Systems)
►▼ Show Figures

Figure 1

17 pages, 4788 KiB  
Article
Itraconazole and Difluorinated-Curcumin Containing Chitosan Nanoparticle Loaded Hydrogel for Amelioration of Onychomycosis
by Prashant Kesharwani, Mahak Fatima, Vanshikha Singh, Afsana Sheikh, Waleed H. Almalki, Virendra Gajbhiye and Amirhossein Sahebkar
Biomimetics 2022, 7(4), 206; https://doi.org/10.3390/biomimetics7040206 - 21 Nov 2022
Cited by 21 | Viewed by 2684
Abstract
Onychomycosis is a nail infection caused by a fungus, Trichophyton mentagrophytes, that is responsible for major nail infections. The best method suited for treating such infections generally includes a topical remedy. However, conventional oral or topical formulations are associated with various limitations. Therefore, [...] Read more.
Onychomycosis is a nail infection caused by a fungus, Trichophyton mentagrophytes, that is responsible for major nail infections. The best method suited for treating such infections generally includes a topical remedy. However, conventional oral or topical formulations are associated with various limitations. Therefore, a more efficient and compatible formulation is developed in this study. The primary objective of the current study is to formulate and evaluate chitosan nanoparticle-based hydrogel for ameliorating onychomycosis. The sole purpose of this research was to increase the permeation of the lipophilic drug itraconazole and difluorinated curcumin, and its synergistic antifungal activity was also evaluated for the first time. Both in vitro and ex vivo drug release evaluations confirmed the sustained release of both drugs from the hydrogel, which is a prerequisite for treating onychomycosis. The results overall highlighted the promising activity of a synergistic approach that could be implemented for the treatment of onychomycosis. The hydrogel-based formulation serves as an effective method of delivery of drugs across the layers of the skin, resulting from its hydrating characteristics. Full article
(This article belongs to the Special Issue Biomimetic Drug Delivery Systems)
►▼ Show Figures

Figure 1

16 pages, 5983 KiB  
Article
Microencapsulation of Lacticaseibacillus rhamnosus GG for Oral Delivery of Bovine Lactoferrin: Study of Encapsulation Stability, Cell Viability, and Drug Release
by Yasir Anwar, Ihsan Ullah, Tahseen Kamal and Muhammad Wajid Ullah
Biomimetics 2022, 7(4), 152; https://doi.org/10.3390/biomimetics7040152 - 04 Oct 2022
Cited by 5 | Viewed by 1963
Abstract
Probiotics are delivered orally for treating gastrointestinal tract (GIT) infections; thus, they should be protected from the harsh environment of the GIT, such as through microencapsulation. Here, we microencapsulated cells of the probiotic Lacticaseibacillus rhamnosus GG via the liquid-droplet-forming method and evaluated them [...] Read more.
Probiotics are delivered orally for treating gastrointestinal tract (GIT) infections; thus, they should be protected from the harsh environment of the GIT, such as through microencapsulation. Here, we microencapsulated cells of the probiotic Lacticaseibacillus rhamnosus GG via the liquid-droplet-forming method and evaluated them for oral delivery of bovine lactoferrin (bLf). Briefly, sodium alginate capsules (G-capsules) were first prepared, crosslinked with calcium chloride (C-capsules), and then modified with disodium hydrogen phosphate (M-capsules). All capsules showed good swelling behavior in the order of G-capsules > C-capsules > M-capsules in simulated gastric fluid (SGF, pH 2) and simulated intestinal fluid (SIF, pH 7.2). FE-SEM observations showed the formation of porous surfaces and successful microencapsulation of L. rhamnosus GG cells. The microencapsulated probiotics showed 85% and 77% viability in SGF and SIF, respectively, after 300 min. Compared to the 65% and 70% viability of gelation-encapsulated and crosslinking-encapsulated L. rhamnosus GG cells, respectively, the mineralization-encapsulated cells showed up to 85% viability after 300 min in SIF. The entrapment of bLf in the mineralization-encapsulated L. rhamnosus GG cells did not show any toxicity to the cells. FTIR spectroscopy confirmed the successful surface modification of L. rhamnosus GG cells via gelation, crosslinking, and mineralization, along with the entrapment of bLf on the surface of microencapsulated cells. The findings of these studies show that the microencapsulated L. rhamnosus GG cells with natural polyelectrolytes could be used as stable carriers for the oral and sustainable delivery of beneficial biotherapeutics without compromising their viability and the activity of probiotics. Full article
(This article belongs to the Special Issue Biomimetic Drug Delivery Systems)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop